Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report)’s share price reached a new 52-week high on Monday . The stock traded as high as $52.83 and last traded at $52.83, with a volume of 0 shares traded. The stock had previously closed at $52.83.
Analyst Upgrades and Downgrades
Separately, HC Wainwright upgraded shares of Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.
Read Our Latest Stock Analysis on BPMUF
Basilea Pharmaceutica Price Performance
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- How to trade using analyst ratings
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
